Healios K.K. (TYO:4593)

Market Cap	63.11B
Revenue (ttm)	588.00M
Net Income (ttm)	-4.37B
Shares Out	101.46M
EPS (ttm)	-47.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,795,500
Average Volume	14,661,345
Open	632.00
Previous Close	622.00
Day's Range	622.00 - 654.00
52-Week Range	133.00 - 747.00
Beta	1.35
RSI	59.47
Earnings Date	Aug 13, 2025

About Everbridge

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4593

Financial Performance

In 2024, Healios K.K.'s revenue was 560.00 million, an increase of 362.81% compared to the previous year's 121.00 million. Losses were -4.24 billion, 10.8% more than in 2023.